large vessel vasculitis or inflammatory arthritis) alongside clinical and patient reported outcomes? 12. Which biomarkers may be useful in PMR? Why do some patients do better than others? How can we identify these groups and what is the biological mechanism behind it? Should different drugs be applied to different PMR subgroups? 13. What is the morbidity and mortality of PMR patients (with a particular focus on cardiovascular risk) in long-term observational studies? There are no studies